Leerink initiates Zimmer Biomet stock coverage with Market Perform By Investing.com

Leerink Partners initiated Zimmer Biomet at Market Perform with a $101 target, implying limited upside from around $93 versus InvestingPro fair value of $113.46. The firm said 2026 revenue and EPS estimates are broadly in line with consensus, but near-term growth remains sensitive to market share shifts and pricing, keeping the stock a 'show me' story. Longer-term upside could come in 2027+ from the semi-autonomous mBôs robot launch in 1H27 and the fully autonomous version in late 2027 or early 2028, alongside ongoing buybacks and sales-force restructuring.

Analysis

ZBH is in the awkward middle of the medtech cycle: the stock can rerate on buybacks and cost discipline, but durable multiple expansion needs evidence that product launches are translating into share gains before the 2027–28 robot cadence. That creates a fairly clean bifurcation: near-term earnings can look fine while the market keeps discounting the name as a low-growth incumbent, especially if pricing stays the main lever. In that setup, peers with cleaner organic-growth narratives should continue to command the premium, and ZBH risks being treated more like a capital-return story than a growth story.

The key second-order effect is that management’s restructuring can lift efficiency, but it also raises execution risk in the sales channel exactly when competitors are pressing for incremental share in orthopedics. If rep productivity improves, the payoff is delayed; if it disappoints, the market will likely punish the stock twice — once on slower revenue inflection and again on skepticism around the launch pipeline. The upside case is therefore less about 2026 and more about a credible bridge to 2027, when the installed base and launch mix can start compounding.

Consensus appears to be underestimating how much optionality sits in the buyback engine versus how little the market is paying for it. If free cash flow remains stable and the repurchase pace stays aggressive, downside should be buffered even without a growth re-rating, which makes the name attractive for relative-value long-only holders but less compelling as a standalone momentum trade. The contrarian angle is that the current discount may already price in most of the near-term disappointment, so a modest beat-and-raise or even just evidence of stable share could drive a sharper reaction than the cautious guidance implies.

Key Decisions for Investors

• Maintain/initiates a small long ZBH position only on weakness toward the low-90s with a 6–12 month horizon; target a rerating toward the low-100s on sustained buyback support, but keep sizing modest because 2026 is unlikely to be the inflection year.
• Use ZBH as a pair trade long vs. a higher-multiple orthopedics peer basket (e.g., ZBH long / SYK or GMED short) if the goal is valuation mean reversion rather than outright growth; thesis: ZBH has more downside protection from capital returns, while peers are more exposed to a disappointment in procedural growth.
• Avoid chasing the stock ahead of the 2027 robot launch cycle; the best risk/reward for a directional long likely comes 2–3 quarters before launch visibility improves, not now when the market is still trading on skepticism.
• For catalyst-driven traders, sell downside puts or structure a cautious call spread over 6–9 months to monetize the high implied uncertainty around execution, while capping exposure to the 'show me' narrative.
• If upcoming quarters show flat-to-modestly positive share commentary plus continued aggressive repurchases, add to longs on confirmation; if pricing pressure reaccelerates or rep productivity slips, cut exposure quickly because the stock could de-rate back to a pure no-growth industrial-medtech multiple.